HER2 as a therapeutic target in the gastric cancer: is it sufficient?
Open Access
- 1 June 2012
- journal article
- editorial
- Published by Springer Nature in Indian Journal of Gastroenterology
- Vol. 31 (3) , 103-105
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- HER2 status in gastro‐oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH)Histopathology, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Helicobacter pylori: gastric cancer and beyondNature Reviews Cancer, 2010
- Novel anticancer targets: revisiting ERBB2 and discovering ERBB3Nature Reviews Cancer, 2009
- A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast CancerCancer Cell, 2007
- Targeting HER proteins in cancer therapy and the role of the non-target HER3British Journal of Cancer, 2007
- Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast CancerJNCI: Journal of the National Cancer Institute, 2007
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- The ErbB receptors and their role in cancer progressionExperimental Cell Research, 2003